专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

KR20180029841A 중간엽 줄기세포 또는 ＡｇＲＰ를 포함하는 유비퀴틴 프로테아좀 활성 증가를 통한 퇴행성 뇌질환 치료제 审中-公开
标题翻译：通过间充质干细胞和AgRP增强蛋白酶体活性治疗神经退行性疾病
公开(公告)号：KR20180029841A
公开(公告)日：2018-03-21
申请号：KR20170085410
申请日：2017-07-05
申请人： SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
发明人： CHANG JONG WOOK , NA DUK L , LEE NA KYUNG
IPC分类号： A61K35/28 , A23L33/13 , A23L33/18 , A61K35/35 , A61K35/50 , A61K35/51 , A61K48/00 , G01N33/68
CPC分类号： A61K35/28 , A23L33/13 , A23L33/18 , A23V2002/00 , A23V2200/322 , A61K35/35 , A61K35/50 , A61K35/51 , A61K48/00 , G01N33/6872
摘要： 일양상에따른중간엽줄기세포, AgRP 또는그의활성단편을포함하는조성물은유비퀴틴프로테아좀의활성을증가시켜유비퀴틴프로테아좀활성감소와관련된질환, 예를들면, 퇴행성뇌질환의예방, 치료, 또는개선에유용하게사용될수 있는효과가있다.
摘要翻译：组合物，包含间充质干细胞，AgRP的或它们的活性片段在根据一个方面是增加的一些泛素蛋白酶体泛素蛋白酶体的疾病，其与降低的活性相关联的活动，例如，预防，治疗退化性脑疾病的，有一个效果可以有效地用于改进。

2. 发明公开

KR20180054439A 세포 3D 배양 방법 审中-公开
公开(公告)号：KR20180054439A
公开(公告)日：2018-05-24
申请号：KR20170143583
申请日：2017-10-31
申请人： GWANGJU INST SCIENCE & TECH , SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
发明人： LEE JAE YOUNG , CHANG JONG WOOK , PARK JUNG GEON , CHOI GO EUN
IPC分类号： C12N5/0775 , C12N5/00
摘要： 본발명은알긴산을포함하는마이크로캡슐, 상기마이크로캡슐의제조방법상기마이크로캡슐을이용한줄기세포의삼차원배양방법및, 상기마이크로캡슐의줄기세포배양용도에관한것으로, 줄기세포를삼차원으로배양할수 있는마이크로크기의캡슐구조를알긴산또는세포외기질유래의펩타이드로변형된알긴산으로형성하여, 일반적으로사용되는배양접시를이용하는이차원배양에서보다공간적, 시간적효율성증대, 세포활성, 대량생산이가능한효율적배양을할 수있다.

3. 发明公开

KR20180024223A 중간엽 줄기세포 분비 단백질을 포함하는 말초신경 세포 증식 촉진용 조성물 审中-公开
标题翻译：诱导周围神经细胞增殖的组合物，其包含间充质干细胞分泌蛋白
公开(公告)号：KR20180024223A
公开(公告)日：2018-03-08
申请号：KR20160110009
申请日：2016-08-29
申请人： SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
发明人： CHOI BYUNG OK , CHANG JONG WOOK
IPC分类号： C12N5/079 , A61K35/30
CPC分类号： A61K35/30
摘要： 본발명은중간엽줄기세포에서분비되는단백질을포함하는말초신경세포증식촉진용조성물, 및상기단백질을포함하는말초신경세포증식용배지조성물에관한것이다. 또한, 본발명은중간엽줄기세포에서분비되는단백질을이용한말초신경세포의증식촉진방법및 이에의하여증식이촉진된말초신경세포및 이를포함하는세포치료제에관한것이다. 본발명에따른중간엽줄기세포에서분비되는단백질은말초신경세포, 특히슈반세포를효과적으로증식시키는바, 세포치료제로이용될수 있는말초신경세포의대량생산을가능하게하므로, 신경질환의효과적인치료제개발에유익할것으로기대된다.
摘要翻译：本发明涉及包含由间充质干细胞分泌的蛋白质的促进末梢神经细胞增殖的组合物，以及包含该蛋白质的促进末梢神经细胞增殖的培养基组合物。此外，本发明涉及使用由间充质干细胞分泌的蛋白质，由此促进增殖的周围神经细胞和包含周围神经细胞的细胞治疗剂来促进周围神经细胞增殖的方法。由本发明的间充质干细胞分泌的蛋白质能够有效地增殖末梢神经细胞，特别是雪旺细胞，并且能够大量生产可用作细胞治疗剂的末梢神经细胞，并且因此预期在开发对神经疾病有效的治疗剂方面是有效的。

4. 发明专利

AU2021252383A1 Stem cell culturing method for promoting initial yield of stem cel.ls 未知
公开(公告)号：AU2021252383A1
公开(公告)日：2022-11-03
申请号：AU2021252383
申请日：2021-04-06
申请人： ENCELL CO LTD , SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
发明人： CHANG JONG WOOK , JEON HONG BAE , PARK SANG EON
IPC分类号： C12N5/0775
摘要： The present invention provides a method for culturing mesenchymal stem cells, comprising initially culturing umbilical cord-derived mesenchymal stem cells under hypoxia conditions at an oxygen partial pressure of 1-8% and 1.0-8.0 PSI pressure conditions. The method for culturing umbilical cord-derived mesenchymal stem cells, according to the present invention, enables stem cell properties to be maintained by inhibiting the differentiation of stem cells, and particularly can achieve a remarkably high proliferation rate.

5. 发明专利

AU2019404719B2 Fusion protein comprising human lefty a protein variants and use thereof 未知
公开(公告)号：AU2019404719B2
公开(公告)日：2022-06-02
申请号：AU2019404719
申请日：2019-12-17
申请人： CHONG KUN DANG PHARMACEUTICAL CORP , SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
发明人： JEONG SUN-YOUNG , LEE KYOUNG WOO , MOON SEUNG KEE , KANG SUNG JUN , CHOI BYUNG-OK , KWAK GEON , CHANG JONG WOOK , KIM JONG HYUN
IPC分类号： C07K14/495 , A61K38/00 , A61P21/00
摘要： The present invention relates to a human Lefty A protein variant with improved productivity and stability, a fusion protein comprising the protein variant, and a composition for preventing and/or treating neuromuscular disease comprising the protein variant or the fusion protein. According to the present invention, a human Lefty A protein variant and a fusion protein comprising the variant are constructed, which have better stability than naturally occurring human Lefty A protein, and thus are expressed at high levels and produced in high yield in animal cells. In addition, administration of the constructed human Lefty A protein variant or fusion protein can restore the nerve and motor functions of nerve disease model animals. Accordingly, the use of the human Lefty A protein variant or fusion protein can effectively prevent or treat various nerve diseases and muscle diseases.

6. 发明专利

AU2021239708A1 Pharmaceutical composition, for preventing or treating Charcot-Marie-Tooth disorder, comprising mesenchymal stem cells or insulin secreted by mesenchymal stem cells 未知
公开(公告)号：AU2021239708A1
公开(公告)日：2022-11-24
申请号：AU2021239708
申请日：2021-01-22
申请人： SAMSUNG LIFE PUBLIC WELFARE FOUNDATION , ENCELL CO LTD
发明人： CHANG JONG WOOK , JEON HONG BAE , PARK SANG EON , OH SHIN JI
IPC分类号： A61K35/28 , A61K38/28 , A61P25/02
摘要： The present invention relates to a pharmaceutical composition, for preventing or treating Charcot-Marie-Tooth disorder, comprising mesenchymal stem cells or insulin secreted by mesenchymal stem cells.

7. 发明专利

AU2019404719A1 Fusion protein comprising human lefty a protein variants and use thereof 未知
公开(公告)号：AU2019404719A1
公开(公告)日：2021-08-12
申请号：AU2019404719
申请日：2019-12-17
申请人： CHONG KUN DANG PHARMACEUTICAL CORP , SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
发明人： JEONG SUN-YOUNG , LEE KYOUNG WOO , MOON SEUNG KEE , KANG SUNG JUN , CHOI BYUNG-OK , KWAK GEON , CHANG JONG WOOK , KIM JONG HYUN
IPC分类号： C07K14/495 , A61K38/00 , A61P21/00
摘要： The present invention relates to a human Lefty A protein variant with improved productivity and stability, a fusion protein comprising the protein variant, and a composition for preventing and/or treating neuromuscular disease comprising the protein variant or the fusion protein. According to the present invention, a human Lefty A protein variant and a fusion protein comprising the variant are constructed, which have better stability than naturally occurring human Lefty A protein, and thus are expressed at high levels and produced in high yield in animal cells. In addition, administration of the constructed human Lefty A protein variant or fusion protein can restore the nerve and motor functions of nerve disease model animals. Accordingly, the use of the human Lefty A protein variant or fusion protein can effectively prevent or treat various nerve diseases and muscle diseases.

8. 发明专利

CA3124338A1 FUSION PROTEIN COMPRISING HUMAN LEFTY A PROTEIN VARIANTS AND USE THEREOF 未知
公开(公告)号：CA3124338A1
公开(公告)日：2020-06-25
申请号：CA3124338
申请日：2019-12-17
申请人： CHONG KUN DANG PHARMACEUTICAL CORP , SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
发明人： JEONG SUN-YOUNG , LEE KYOUNG WOO , MOON SEUNG KEE , KANG SUNG JUN , CHOI BYUNG-OK , KWAK GEON , CHANG JONG WOOK , KIM JONG HYUN
IPC分类号： C07K14/495 , A61K38/00 , A61P21/00
摘要： The present invention relates to a human Lefty A protein variant with improved productivity and stability, a fusion protein comprising the protein variant, and a composition for preventing and/or treating neuromuscular disease comprising the protein variant or the fusion protein. According to the present invention, a human Lefty A protein variant and a fusion protein comprising the variant are constructed, which have better stability than naturally occurring human Lefty A protein, and thus are expressed at high levels and produced in high yield in animal cells. In addition, administration of the constructed human Lefty A protein variant or fusion protein can restore the nerve and motor functions of nerve disease model animals. Accordingly, the use of the human Lefty A protein variant or fusion protein can effectively prevent or treat various nerve diseases and muscle diseases.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式